In a report published Thursday, Morgan Stanley analyst David Risinger reiterated an Equal-Weight rating on AbbVie ABBV, but removed the $47.00 price target.
In the report, Morgan Stanley noted, “ABT-199 is a potential blockbuster blood cancer treatment that ABBV and Roche could launch in '16. In the U.S., ABBV and Roche will share profits/losses equally. Ex-U.S., ABBV will book sales and pay Roche a royalty (undisclosed). We highlight upcoming events below.”
AbbVie closed on Wednesday at $50.63.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in